Trial Profile
Phase II Study of CPX-351 (Cytarabine:Daunorubicin) Liposome Injection in Patients With Newly Diagnosed AML at High Risk for Induction Mortality
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Cytarabine/daunorubicin (Primary)
- Indications Acute myeloid leukaemia
- Focus Therapeutic Use
- 01 Nov 2020 Results published in the Leukemia
- 27 Jan 2020 Status changed from active, no longer recruiting to completed.
- 29 May 2019 Planned End Date changed from 1 May 2021 to 31 May 2021.